Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics

Assembly Biosciences, Inc. (ASMB)

Today's Latest Price: $5.69 USD

0.03 (0.53%)

Updated Dec 2 4:00pm

Add ASMB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ASMB Stock Summary

  • The ratio of debt to operating expenses for Assembly Biosciences Inc is higher than it is for about just 10.02% of US stocks.
  • As for revenue growth, note that ASMB's revenue has grown 454.77% over the past 12 months; that beats the revenue growth of 98.41% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ASMB comes in at -74.54% -- higher than that of only 4.88% of stocks in our set.
  • Stocks that are quantitatively similar to ASMB, based on their financial statements, market capitalization, and price volatility, are BLUE, APTX, NERV, CLLS, and NKTR.
  • Visit ASMB's SEC page to see the company's official filings. To visit the company's web site, go to

ASMB Stock Price Chart Interactive Chart >

Price chart for ASMB

ASMB Price/Volume Stats

Current price $5.69 52-week high $27.84
Prev. close $5.66 52-week low $4.78
Day low $5.51 Volume 913,400
Day high $5.75 Avg. volume 462,315
50-day MA $11.99 Dividend yield N/A
200-day MA $17.75 Market Cap 187.90M

Assembly Biosciences, Inc. (ASMB) Company Bio

Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.

ASMB Latest News Stream

Event/Time News Detail
Loading, please wait...

ASMB Latest Social Stream

Loading social stream, please wait...

View Full ASMB Social Stream

Latest ASMB News From Around the Web

Below are the latest news stories about Assembly Biosciences Inc that investors may wish to consider to help them evaluate ASMB as an investment opportunity.

Assembly Bio HBV core inhibitors show positive action in studies

Assembly Biosciences (ASMB) announces clinical data on lead HBV core inhibitor vebicorvir (ABI-H0731) and second-generation core inhibitor ABI-H2158. The results were virtually presented at the European Association for the Study of the Liver ((EASL)) Annual Meeting.Vebicorvir, combined with nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy in patients with HBeAg-negative chronic hepatitis...

Seeking Alpha | August 28, 2020

Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company…

GlobeNewswire | August 5, 2020

The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer ...

Benzinga | July 22, 2020

Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million…

GlobeNewswire | July 20, 2020

BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge

BeiGene (BGNE) and Assembly Biosciences (ASMB) have announced a new collaboration in China for Assembly’s three clinical-stage core inhibitor candidates for the treatment of chronic … The post BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge appeared first on Smarter Analyst .

Smarter Analyst | July 20, 2020

Read More 'ASMB' Stories Here

ASMB Price Returns

1-mo -61.42%
3-mo -70.29%
6-mo -74.14%
1-year -65.30%
3-year -88.18%
5-year -32.90%
YTD -72.19%
2019 -9.55%
2018 -50.01%
2017 272.43%
2016 61.78%
2015 -4.45%

Continue Researching ASMB

Want to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:

Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7545 seconds.